Neoadjuvant chemotherapy followed by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer: a feasibility and safety study

• Published in: World journal of surgical oncology Vol. 17; no. 1; p. 14
• Main Authors: Leimkühler, M, Hemmer, P H J, Reyners, A K L, de Groot, D J A, van Ginkel, R J, Been, L B, de Bock, G H, van Leeuwen, B L
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 11.01.2019; BioMed Central; BMC
• Subjects: Adjuvant chemotherapy; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biopsy; Cancer metastasis; Cancer research; Cancer therapies; Cancer treatment; Carcinoma; Care and treatment; CAT scans; Chemotherapy; Chemotherapy, Adjuvant; Chemotherapy, Cancer, Regional Perfusion; Colorectal cancer; Colorectal carcinoma; Colorectal Neoplasms - pathology; Colorectal Neoplasms - therapy; Combined Modality Therapy; Complications; Computed tomography; Cytoreduction Surgical Procedures; Debulking; Feasibility Studies; Female; Follow-Up Studies; Gastric cancer; HIPEC; Humans; Hyperthermia, Induced; Liver; Male; Medical research; Metastases; Metastasis; Middle Aged; Neoadjuvant chemotherapy; Neoadjuvant Therapy; Oxaliplatin; Patients; Peritoneal carcinomatosis; Peritoneal Neoplasms - pathology; Peritoneal Neoplasms - therapy; Peritoneum; Postoperative complications; Prognosis; Safety; Surgery; Surgical outcomes; Survival Rate; Tomography; Toxicity; Tumors; Neoadjuvant chemotherapy; HIPEC; Colorectal cancer; Peritoneal carcinomatosis

Standard treatment for colorectal peritoneal carcinomatosis typically involves cytoreductive surgery, hyperthermic intraperitoneal chemotherapy (HIPEC), and if possible, postoperative adjuvant chemotherapy. However, a substantial percentage of patients never receive adjuvant chemotherapy because of...